The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Role of FDG-PET-CT (PET) in predicting outcome of advanced hepatocellular carcinoma (aHCC) patients (pts) treated with sorafenib (SB): A prospective controlled study.
Roberto A. Pazo Cid
No relevant relationships to disclose
Javier Martinez Trufero
No relevant relationships to disclose
M. Lanzuela
No relevant relationships to disclose
Javier Fuentes
No relevant relationships to disclose
Miguel A Ubieto
No relevant relationships to disclose
Javier Banzo
No relevant relationships to disclose
Luis Sarriá
No relevant relationships to disclose
José María Artigas
No relevant relationships to disclose
Carlos Hördnler
No relevant relationships to disclose
Angel Artal
No relevant relationships to disclose
Teresa Puértolas
No relevant relationships to disclose
Alejandro Serrablo
No relevant relationships to disclose
Maite Soria
No relevant relationships to disclose
Elena Barrao
No relevant relationships to disclose
Ana Cebollero
No relevant relationships to disclose
Lourdes Calera
No relevant relationships to disclose
Isabel Pajares
No relevant relationships to disclose
Alba Hernández García
No relevant relationships to disclose
Jorge Hernando Cubero
No relevant relationships to disclose
Antonio Anton
No relevant relationships to disclose